News

Valeant Pharmaceuticals has provided update on the regulatory applications to the FDA and the European Medicines Agency (EMEA) for the investigational drug retigabine, a neuronal potassium channel opener

MedImmune has revealed that the US Department of Health and Human Services (HHS) has placed an order for an additional 29 million doses of its live attenuated influenza

Provectus Pharmaceuticals has completed the treatment portion, including all protocol-allowed retreatments of all patients, of phase 2 clinical trial of PV-10 for metastatic melanoma. PV-10 is a injectable

King Pharmaceuticals has announced the commercial availability for EMBEDA (morphine sulfate and naltrexone hydrochloride) extended release capsules, a long-acting Schedule II opioid analgesic for the management of moderate

AstraZeneca and Nektar Therapeutics have entered into an agreement for two drug development programmes: NKTR-118, a late stage investigational product being evaluated for the treatment of opioid-induced constipation,

Dalton Pharma Services (Dalton) has expanded its pharmaceutical manufacturing services by adding formulation development to its list of integrated capabilities. Reportedly, Dalton’s analytical, process and formulation scientists are

Enzo Biochem has entered into a Cooperative Research and Development Agreement (CRADA) with the National Eye Institute, part of the National Institute of Health, to conduct a human

Incyte has announced positive clinical trial results for a topical formulation of its lead janus kinase (JAK) inhibitor, INCB18424, in psoriasis. The results were obtained from a multi-center

DOR BioPharma has announced that it has been awarded an approximate $9.4m grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National